BCM
NVCR icon

BlueCrest Capital Management’s NovoCure NVCR Stock Holding History

BlueCrest Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,308
Closed -$546K – 519
2019
Q3 		$546K Buy
+7,308
New +$584K 0.04% 254
2019
Q2 		– Sell
-7,207
Closed -$347K – 847
2019
Q1 		$347K Buy
+7,207
New +$347K 0.01% 637

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

BlueCrest Capital Management's NVCR Position: Q4 2019 in Review

BlueCrest Capital Management sold out of NovoCure (NVCR) in Q4 2019, closing a stake of 7,308 shares — an estimated $546K sold.

BlueCrest Capital Management first reported a position in NVCR in Q1 2019 and held it in 2 quarters. The position peaked at $546K in Q3 2019. 262 funds tracked by Wall St. Rank hold NVCR as of Q4 2019.

  • BlueCrest Capital Management reported no remaining NovoCure position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 7,308 NovoCure shares in Q4 2019, an estimated $546K.
  • BlueCrest Capital Management first reported a position in NovoCure in Q1 2019 and held it in 2 quarters.
  • BlueCrest Capital Management's NovoCure position peaked at $546K in Q3 2019.
  • 262 funds tracked by Wall St. Rank held NovoCure as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.